1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Ono, Kyowa, BMS partner in immunotherapy combos

 
• By Ian Haydock

The efficacy promise presented by combinations of new cancer immunotherapies was a major factor behind Pfizer's recent huge alliance with Merck KGaA. On a smaller scale, it is now the driving force behind a new planned clinical study in Japan with Ono Pharmaceutical and Bristol-Myers Squibb's first-in-class PD-1 immune checkpoint inhibitor.

The efficacy promise presented by combinations of new cancer immunotherapies was a major factor behind Pfizer's recent huge alliance with Merck KGaA. On a smaller scale, it is now the driving force behind a new planned clinical study in Japan with Ono Pharmaceutical and Bristol-Myers Squibb's first-in-class PD-1 immune checkpoint inhibitor.

The Phase I trial will assess the antibody Opdivo (nivolumab) in combination with mogamulizumab, Kyowa Hakko Kirin's anti-CCR4 antibody. Ono...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

More from Therapy Areas

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.